Oral Squamous Cell Carcinoma: The Role of BIRC6 Serum Level

Banakar, Morteza; Ardekani, Shima Torabi; Zare, Razieh; Malekzadeh, Mahyar; Mirhadi, Hossein; Khademi, Bijan; Rokaya, Dinesh

doi:10.1155/2022/5425478

Cited by 6 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study found that BIRC6 was overexpressed in OSCC cases, and to the best of our knowledge, this is the first report to clarify BIRC6 expression in OSCC. However, Banakar et al assessed the serum level of BIRC6 in OSCC and found no significant difference in the serum levels of BIRC6 between patients with OSCC and healthy individuals [35]. Other studies have also investigated antiapoptotic markers in OSCC.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of BIRC6 Expression in Oral Squamous Cell Carcinoma, Epithelial Dysplasia, Lichen Planus with and without Dysplasia, and Hyperkeratosis

Eskandari,

Razavian,

Zare

et al. 2023

Diagnostics

Self Cite

View full text Add to dashboard Cite

Background: BIRC6, regarded as the pivotal member of the inhibitor of the apoptosis (IAP) family, has been linked to the development of different types of cancer in humans. The objective of this study was to examine the expression of BIRC6 in various oral conditions, including OLP with dysplasia (OLPD), hyperkeratosis (HK), OLP, epithelial dysplasia (ED), and oral squamous cell carcinoma (OSCC), to investigate its potential involvement in the development of OSCC and the pathogenesis and malignant transformation of OLP, which is known as a precancerous condition. Methods: In this retrospective cross-sectional study, 99 cases, consisting of 19 cases of OSCC, 21 cases of ED, 23 cases of OLP, 20 cases of OLPD, and 16 cases of HK as the control group, were investigated regarding BIRC6 expression by immunohistochemical staining. After that, the immunohistochemical expression of BIRC6 in the epithelial compartment was analyzed. Statistical analysis was performed to investigate the relationship between the expression of BIRC6 and clinicopathological variables. The statistical analysis of the data involved the use of one-way ANOVA, post hoc Tukey, Kruskal–Wallis, Chi-square, Spearman’s correlation, and Mann–Whitney tests. The significance level was set at p < 0.05. Results: Positive BIRC6 staining was found in 91.7% of the subjects of OLP, 88.1% of HK, 86.1% of ED, 93% of OLPD, and 94.7% of OSCC. OSCC showed the highest BIRC6 expression (p = 0.00). The average total staining score was remarkably greater in OSCC and dysplastic lesions compared with HK (p = 0.00, p = 0.00). Conclusions: While the current study suggested that BIRC6 may play a role in the tumorigenesis of OSCC, its role in the malignant transformation of OLP has yet to be definitively established.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of BIRC6 Expression in Oral Squamous Cell Carcinoma, Epithelial Dysplasia, Lichen Planus with and without Dysplasia, and Hyperkeratosis

Eskandari,

Razavian,

Zare

et al. 2023

Diagnostics

Self Cite

View full text Add to dashboard Cite

show abstract

“…We also suggested that upregulation of CD274 inhibited proliferation and invasion of A549 cells and increased apoptosis in lung cancer cells. The CD274 gene encodes PD-L1, a major co-inhibitory checkpoint signal that controls T-cell activity ( 53 , 54 ). A study showed a significant increase in PD-L1 in shGBE1 A549 cells and a negative correlation between PD-L1 and GBE1 ( 55 ).…”

Section: Discussionmentioning

confidence: 99%

Correlation of tumor mutational burden with prognosis and immune infiltration in lung adenocarcinoma

Li²

2023

Front. Oncol.

View full text Add to dashboard Cite

BackgroundTumor mutational burden (TMB) plays an important role in the evaluation of immunotherapy efficacy in lung adenocarcinoma (LUAD).ObjectiveTo improve the clinical management of LUAD by investigating the prognostic value of TMB and the relationship between TMB and immune infiltration.MethodsTMB scores were calculated from the mutation data of 587 LUAD samples from The Cancer Genome Atlas (TCGA), and patients were divided into low-TMB and high-TMB groups based on the quartiles of the TMB score. Differentially expressed genes (DEGs), immune cell infiltration and survival analysis were compared between the low-TMB and high-TMB groups. We queried the expression of genes in lung cancer tissues through the GEPIA online database and performed experimental validation of the function of aberrant genes expressed in lung cancer tissues.ResultsWe obtained sample information from TCGA for 587 LUAD patients, and the results of survival analysis for the high- and low- TMB groups suggested that patients in the high-TMB group had lower survival rates than those in the low-TMB group. A total of 756 DEGs were identified in the study, and gene set enrichment analysis (GSEA) showed that DEGs in the low-TMB group were enriched in immune-related pathways. Among the differentially expressed genes obtained, 15 immune-related key genes were screened with the help of ImmPort database, including 5 prognosis-related genes (CD274, PDCD1, CTLA4, LAG3, TIGIT). No difference in the expression of PDCD1, CTLA4, LAG3, TIGIT in lung cancer tissues and differential expression of CD274 in lung cancer tissues.ConclusionsThe survival rate of LUAD patients with low TMB was better than that of LUAD patients with high TMB. CD274 expression was down regulated in human LUAD cell lines H1299, PC-9, A549 and SPC-A1, which inhibited malignant progression of A549 cells.

show abstract

“…However due to the great genetic and epigenetic heterogeneity of this tumor, identifying a sensitive and specific biomarker has remained a challenge. 2 , 3 , 4 …”

Section: Introductionmentioning

confidence: 99%